Active Recombinant Human EPHA2 Protein (Gln25-Asn534), C-6×His tagged

• Cat.No.: EPHA2-27H
• Product Overview: Recombinant human EPHA2 protein (Gln25-Asn534) with a C-terminal 6×His tag was expressed in Mouse myeloma cell line.

Specification

• Description: This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Mutations in this gene are the cause of certain genetically-related cataract disorders.
• Source: Mouse myeloma cell line
• Species: Human
• Tag: His
• Bio-activity: Measured by its binding ability in a functional ELISA. Immobilized rhEphA2 at 2 μg/mL (100 μL/well) can bind rmEphrin-A1/Fc Chimera with a linear range of 0.078-5 ng/mL.
• Molecular Mass: Predicted Molecular Mass: 56.9 kDa
  SDS-PAGE: 70-75 kDa, reducing conditions
• Protein length: Gln25-Asn534
• N-terminal Sequence Analysis: No results obtained: Gln25 predicted & Lys27
• Endotoxin: < 0.10 EU/μg of the protein by the LAL method.
• Purity: > 95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 centigrade as supplied.
  1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
  3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
• Storage Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Reconstitution: Reconstitute at 100 μg/mL in sterile PBS.
• Shipping: The product is shipped at ambient temperature.

Gene Information

• Gene Name: EPHA2 EPH receptor A2 [ Homo sapiens (human) ]
• Official Symbol: EPHA2
• Synonyms: EPHA2; EPH receptor A2; ECK, EphA2; ephrin type-A receptor 2; soluble EPHA2 variant 1; tyrosine-protein kinase receptor ECK; epithelial cell receptor protein tyrosine kinase; ECK; CTPA; ARCC2; CTPP1
• Gene ID: 1969
• mRNA Refseq: NM_004431
• Protein Refseq: NP_004422
• MIM: 176946
• UniProt ID: P29317

Reviews

12/21/2022

The protein has low cytotoxicity.

02/03/2022

EPHA2 has good stability, and the test results of heat resistance, acid and alkali resistance and protease degradation resistance are good.

03/31/2021

Kinetic parameters such as enzymatic reaction rate and binding affinity were tested, and the protein performed well.

Q&As

What are the treatment strategies for EPHA2?

Therapeutic strategies for EPHA2 include inhibition of its expression, blocking its signal transduction pathway, and modulating its interaction with ligands. These strategies may involve the use of small molecule inhibitors, antibodies, or other types of therapeutics.

How does EPHA2 expression level relate to the occurrence and progression of the disease?

The expression level of EPHA2 is associated with the occurrence and progression of a variety of diseases. For example, in tumors such as lung, breast, and colorectal cancer, EPHA2 expression levels may be elevated and correlated with the degree of malignancy and poor prognosis of the tumor.

How does EPHA2 expression level relate to tumor prognosis?

In some tumors, EPHA2 expression levels are associated with poor prognosis in patients. For example, patients with lung cancer who express EPHA2 often have shorter survival. Therefore, the expression level of EPHA2 may be one of the indicators to predict tumor prognosis.

How can diseases be diagnosed by detecting EPHA2 expression levels?

Some diseases can be diagnosed by measuring EPHA2 expression levels, such as immunohistochemistry, western blotting, and real-time PCR.

Could EPHA2 be used as a target for the treatment of certain diseases?

Yes, EPHA2 can be used as a target for the treatment of certain diseases. For example, inhibition of EPHA2 expression can inhibit tumor growth and spread, so EPHA2 can serve as a potential therapeutic target. In addition, regulating the expression level of EPHA2 may also be helpful in the treatment of diseases such as the nervous system and cardiovascular system.

What is the role of EPHA2 in cancer metastasis?

EPHA2 can promote cancer metastasis and affect the spread and spread of cancer by regulating processes such as invasion and migration of tumor cells. Therefore, inhibition of EPHA2 expression or blocking its signal transduction pathway may have a potential therapeutic effect on inhibiting cancer metastasis.